8-K: Aditxt Resolves Dispute with Aldevron, Subsidiary Adimune Advances ADI-100 Towards Clinical Trials

Aditxt settles a dispute with Aldevron by agreeing to pay $1 million and issue a promissory note, while its subsidiary Adimune progresses with ADI-100, an investigational product candidate, aiming for clinical trials in autoimmune diseases.

Summary

• Aditxt, Inc. has entered into a Settlement Agreement with Aldevron, LLC to resolve disputes over previously issued invoices.
• Aditxt will pay Aldevron $1 million in cash and issue a Promissory Note for $824,371.06.
• The promissory note will not bear interest if repaid by the maturity date of May 16, 2025, but will accrue interest at 1.5% per annum if not repaid by then.
• Aditxt's subsidiary, Adimune, Inc., is advancing ADI-100, an investigational product candidate for autoimmune diseases.
• Preclinical studies of ADI-100 have been completed, and the shipment of drug substances for final drug product formulation is planned for March.
• Adimune plans clinical trials for ADI-100 in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.
• Adimune has engaged a Contract Research Organization (CRO) to manage the clinical trial process in Germany.
• Adimune is working with the Mayo Clinic to prepare the IND package for FDA submission, with a pre-IND meeting expected in the second quarter of this year.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the settlement agreement involves a significant financial obligation, the progress of ADI-100 towards clinical trials is a positive development. However, the need to raise capital and the potential failure of the Evofem merger temper the overall sentiment.

Positives

• Aditxt has resolved a dispute with Aldevron, providing clarity on financial obligations.
• Adimune's ADI-100 has completed preclinical studies, showing promising results in restoring immune tolerance.
• ADI-100 has demonstrated a lack of toxicity and does not impair the immune system's ability to combat infection, cancer, or the tumor-fighting capabilities of checkpoint inhibitors in preclinical studies.
• Clinical-grade drug substances for ADI-100 have been successfully manufactured.
• Adimune is progressing towards clinical trials in multiple locations, including Germany and the Mayo Clinic.
• Adimune has had pre-submission meetings with the regulatory agency in Germany and has completed the additional studies requested.

Negatives

• Aditxt is required to make a $1 million cash payment and issue a promissory note for $824,371.06 to settle the dispute with Aldevron, representing a significant financial obligation.
• The promissory note accrues interest at 1.5% per annum if not repaid by May 16, 2025, adding to the financial burden if repayment is delayed.
• The press release mentions that Aditxt needs to raise approximately $17 million for Appili and $17 million for Evofem, and if they fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem.

Risks

• Failure to repay the promissory note by the maturity date could result in additional interest expenses.
• Clinical trials are subject to regulatory approvals and may face delays or rejection.
• The success of ADI-100 in preclinical studies does not guarantee similar results in human clinical trials.
• Aditxt's ability to finance and execute its strategic M&A initiatives is subject to raising sufficient capital.
• The closing of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.
• If Aditxt fails to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem.

Future Outlook

Adimune is moving towards clinical trials for ADI-100 in autoimmune diseases, with plans to submit regulatory filings and initiate trials in Germany and at the Mayo Clinic. Aditxt aims to continue supporting Adimune's progress and expand its innovation platform.

Management Comments

• Dr. Friedrich Kapp, Co-CEO of Adimune, stated that they are moving toward clinical trials and remain focused on executing the necessary steps to ensure the highest standards of safety, efficacy, and regulatory compliance.
• Amro Albanna, Co-Founder, Chairman and CEO of Aditxt, added that the shipment of the drug substance marks a critical step in bringing ADI and ADI-100 to the clinic.

Industry Context

The development of ADI-100 targets the growing market for autoimmune disease treatments. The approach of restoring immune tolerance, rather than immunosuppression, aligns with a trend towards more targeted and potentially safer therapies. Companies like Bristol Myers Squibb and Johnson & Johnson are also investing in autoimmune disease therapies, indicating a significant market opportunity.

Comparison to Industry Standards

• ADI-100's approach of antigen-specific gene therapy to restore immune tolerance is similar in concept to other companies developing targeted immunotherapies, such as Selecta Biosciences with their ImmTOR platform.
• The planned clinical trials in Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome are comparable to trials conducted by companies like Provention Bio (now part of Sanofi) for teplizumab in Type 1 Diabetes.
• The focus on demonstrating safety and efficacy in early-stage clinical trials aligns with industry best practices for drug development.

Stakeholder Impact

• Shareholders may be impacted by the financial obligations related to the settlement agreement and the potential need for capital raising.
• Employees of Adimune may be impacted by the progress of ADI-100 towards clinical trials.
• Patients with autoimmune diseases may benefit from the potential development of ADI-100 as a new treatment option.
• Aldevron will receive payment for the outstanding invoices, resolving the financial dispute.

Next Steps

• Aditxt will make the cash payment and issue the promissory note to Aldevron.
• Aldevron will ship the GMP materials to Aditxt.
• Adimune will formulate the clinical-grade drug substances into the final drug product.
• Adimune will complete stability testing and drug product release assays.
• Adimune will submit regulatory filings for clinical trials in Germany and the U.S.
• Adimune will initiate clinical trials for ADI-100 in Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome.

Key Dates

Keywords

Aditxt, Adimune, ADI-100, Aldevron, Settlement Agreement, Promissory Note, Clinical Trials, Autoimmune Diseases, Type 1 Diabetes, Psoriasis, Stiff Person Syndrome, Regulatory Submissions, Drug Development